Emerging Therapeutic Approaches in MASLD by Mazen Noureddin, MD, MHSc

Dr. Mazen Noureddin, MD, MHSc, served as the inaugural director of the Fatty Liver Program at Cedars-Sinai Medical Center, a facility currently ranked second in Gastroenterology and Gastrointestinal Surgery by US News. Recently, he has relocated from California to Texas, where he is establishing a cutting-edge research institute in Houston.
Dr. Noureddin completed his internal medicine residency at the University of Southern California (USC) before transitioning to the National Institutes of Health (NIH). There, he pursued a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and successfully completed the NIH/Duke University Master of Health Sciences in Clinical Research program. Following his NIH fellowship, he undertook a gastroenterology fellowship at the University of California, San Diego (UCSD), where he held the T32 NIH fellowship.
In 2013, Dr. Noureddin joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine and later, in 2015, was recruited to Cedars-Sinai Medical Center to establish its innovative fatty liver program.
Internationally recognized for his research in Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), and NASH-related cirrhosis, Dr. Noureddin has conducted over 40 investigational clinical studies focusing on novel treatments for NASH. His expertise extends to non-invasive testing and biomarkers for NASH and cirrhosis, and he has published extensively in these areas. He has been invited to participate in consensus panels by prestigious international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of Liver Diseases (EASL). Dr. Noureddin has delivered invited lectures on NAFLD/NASH at national and international society meetings and actively serves on steering committees and advisory boards for the industry.
Notably, he is the vice chair of the AASLD NASH Special Interest Group and is slated to chair the group in 2023. Dr. Noureddin is also a member of the editorial boards for major gastrointestinal journals, including "Gastroenterology," "Hepatology," and "Clinical Gastroenterology and Hepatology (CGH)." He recently took on the role of Associate Editor for "Clinical Gastroenterology and Hepatology (CGH)." His research is supported by funding from the National Cancer Institute, and he has contributed as a reviewer on NIH study sections. Dr. Noureddin's work has been published in prestigious journals such as The Lancet, Science Translational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, and Clinical Gastroenterology and Hepatology, among others.
The current talk was presented at the INEDSYS Hepatology Club meeting on October 7, 2023.